|
Vernalis Pharmaceuticals Inc |
|
|
1140 Headquarters Plaza, 2nd Floor, West Tower
Morristown, NJ 07960 USA
phone:973-867-5555
fax:973-993-1846
|
|
| Symbol |
VNLS |
| Exchange |
NASDAQ |
| Founded |
2003 |
| Employees |
95 |
|
|
| www.vernalis.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pharmaceuticals for Parkinson's disease and migraine treatment. |
|
| Management |
| Peter Fellner, Executive Chairman; Simon Sturge, Chief Executive Officer; Anthony Weir, Chief Financial Officer; John Slater, General Counsel; John Hutchison, Development Director; George Kennedy CBE, Deputy Chairman & Senior Independent Director; Carol Ferguson, Non-executive Director; Peter Read CBE, Non-executive Director; Allan Baxter, Non-executive Director; Ian Clark, Non-executive Director |
| |
|
|
|
|
|
|
|
| Keywords |
| Pharamaceutical, research, drugs, clinical development, migraine, pain, Parkinson's disease |
|
|
|
| Description |
|
Vernalis is a UK-based specialty pharmaceutical company with two marketed products, ApokynŽ to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frovatriptan, to treat migraine. |
|
|
| Competitors / Substitutes / Alternatives |
AstraZeneca PLC, Celltech Group PLC, GlaxoSmithKline PLC
|
|
| Strategy |
The company has a broad development pipeline focused on neurology and central nervous system disorders.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
